Brentuximab is an antibody attached to a chemotherapeutic drug targeted against Hodgkin lymphoma cells. Nivolumab is an antibody that enhances the immune system to better attack Hodgkin lymphoma cells. It has shown that both drugs induce high response rates in relapsed or refractory Hodgkin lymphoma.
PET CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab and RT Free Management in cHL
OPEN TO ACCRUAL